References
Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, et al.(2003). Mechanism of SMRT corepressor recruitment by the BCL6 BTB
domain. Mol Cell 12: 1551-1564.
Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, et
al. (2004). The human BCL6 transgene promotes the development of
lymphomas in the mouse. Proc Natl Acad Sci U S A 101:14198-14203.
Basso K, & Dalla-Favera R (2015). Germinal centres and B cell
lymphomagenesis. Nat Rev Immunol 15: 172-184.
Beguelin W, Teater M, Gearhart MD, Calvo Fernandez MT, Goldstein RL,
Cardenas MG, et al. (2016). EZH2 and BCL6 Cooperate to Assemble
CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center
Formation and Lymphomagenesis. Cancer Cell 30: 197-213.
Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD, Jr., & Melnick AM
(2017). The Expanding Role of the BCL6 Oncoprotein as a Cancer
Therapeutic Target. Clin Cancer Res 23: 885-893.
Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, et
al. (2016). Rationally designed BCL6 inhibitors target activated B cell
diffuse large B cell lymphoma. J Clin Invest 126: 3351-3362.
Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q,
et al. (2005). Deregulated BCL6 expression recapitulates the
pathogenesis of human diffuse large B cell lymphomas in mice. Cancer
Cell 7: 445-455.
Cerchietti L, & Melnick A (2013). Targeting BCL6 in diffuse large
B-cell lymphoma: what does this mean for the future treatment? Expert
Rev Hematol 6: 343-345.
Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M,
et al. (2010). A small-molecule inhibitor of BCL6 kills DLBCL cells in
vitro and in vivo. Cancer Cell 17: 400-411.
Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn
A, et al. (2009). A peptomimetic inhibitor of BCL6 with potent
antilymphoma effects in vitro and in vivo. Blood 113:3397-3405.
Cheng H, Linhares BM, Yu W, Cardenas MG, Ai Y, Jiang W, et al.(2018). Identification of Thiourea-Based Inhibitors of the B-Cell
Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and
Computer-Aided Drug Design. J Med Chem 61: 7573-7588.
Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, et
al. (2009). The BCL6 transcriptional program features repression of
multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood
113: 5536-5548.
Coiffier B, & Sarkozy C (2016). Diffuse large B-cell lymphoma: R-CHOP
failure-what to do? Hematology Am Soc Hematol Educ Program
2016: 366-378.
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin
J, et al. (2017). Outcomes in refractory diffuse large B-cell
lymphoma: results from the international SCHOLAR-1 study. Blood
130: 1800-1808.
Deb D, Rajaram S, Larsen JE, Dospoy PD, Marullo R, Li LS, et al.(2017). Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats
Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers.
Cancer Res 77: 3070-3081.
Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, et
al. (1997). Corepressor SMRT binds the BTB/POZ repressing domain of the
LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 94:10762-10767.
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et
al. (2011). BCL6 enables Ph+ acute lymphoblastic leukaemia cells to
survive BCR-ABL1 kinase inhibition. Nature 473: 384-388.
Fernando TM, Marullo R, Pera Gresely B, Phillip JM, Yang SN,
Lundell-Smith G, et al. (2019). BCL6 Evolved to Enable Stress
Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to
Adapt to Stress. Cancer Discov 9: 662-679.
Homola J (2003). Present and future of surface plasmon resonance
biosensors. Anal Bioanal Chem 377: 528-539.
Huang C, Hatzi K, & Melnick A (2013). Lineage-specific functions of
Bcl-6 in immunity and inflammation are mediated by distinct biochemical
mechanisms. Nat Immunol 14: 380-388.
Huang C, & Melnick A (2015). Mechanisms of action of BCL6 during
germinal center B cell development. Sci China Life Sci 58:1226-1232.
Huynh KD, Fischle W, Verdin E, & Bardwell VJ (2000). BCoR, a novel
corepressor involved in BCL-6 repression. Genes Dev 14:1810-1823.
Kamada Y, Sakai N, Sogabe S, Ida K, Oki H, Sakamoto K, et al.(2017). Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction
Inhibitor by a Biophysics-Driven Fragment-Based Approach. J Med Chem
60: 4358-4368.
Kerres N, Steurer S, Schlager S, Bader G, Berger H, Caligiuri M,
et al. (2017). Chemically Induced Degradation of the Oncogenic
Transcription Factor BCL6. Cell Rep 20: 2860-2875.
Kitano M, Moriyama S, Ando Y, Hikida M, Mori Y, Kurosaki T, et
al. (2011). Bcl6 protein expression shapes pre-germinal center B cell
dynamics and follicular helper T cell heterogeneity. Immunity
34: 961-972.
Leeman-Neill RJ, & Bhagat G (2018). BCL6 as a therapeutic target for
lymphoma. Expert Opin Ther Targets 22: 143-152.
Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontan L, et al.(2018). PRMT5 interacts with the BCL6 oncoprotein and is required for
germinal center formation and lymphoma cell survival. Blood
132: 2026-2039.
Madapura HS, Nagy N, Ujvari D, Kallas T, Krohnke MCL, Amu S, et
al. (2017). Interferon gamma is a STAT1-dependent direct inducer of
BCL6 expression in imatinib-treated chronic myeloid leukemia cells.
Oncogene 36: 4619-4628.
McCoull W, Abrams RD, Anderson E, Blades K, Barton P, Box M, et
al. (2017). Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma
6 (BCL6) Binders and Optimization to High Affinity Macrocyclic
Inhibitors. J Med Chem 60: 4386-4402.
Mendgen T, Steuer C, & Klein CD (2012). Privileged scaffolds or
promiscuous binders: a comparative study on rhodanines and related
heterocycles in medicinal chemistry. J Med Chem 55: 743-753.
Mlynarczyk C, Fontan L, & Melnick A (2019). Germinal center-derived
lymphomas: The darkest side of humoral immunity. Immunol Rev
288: 214-239.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson
CA, et al. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in
Refractory Large B-Cell Lymphoma. N Engl J Med 377: 2531-2544.
Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, &
Dalla-Favera R (2003). Mutations of the BCL6 proto-oncogene disrupt its
negative autoregulation in diffuse large B-cell lymphoma. Blood
101: 2914-2923.
Phan RT, & Dalla-Favera R (2004). The BCL6 proto-oncogene suppresses
p53 expression in germinal-centre B cells. Nature 432: 635-639.
Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva
GF, et al. (2004). Specific peptide interference reveals BCL6
transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat
Med 10: 1329-1335.
Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM,
et al. (2007). Transcriptional signature with differential expression
of BCL6 target genes accurately identifies BCL6-dependent diffuse large
B cell lymphomas. Proc Natl Acad Sci U S A 104: 3207-3212.
Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, et
al. (2007). Bcl-6 mediates the germinal center B cell phenotype and
lymphomagenesis through transcriptional repression of the DNA-damage
sensor ATR. Nat Immunol 8: 705-714.
Ranuncolo SM, Polo JM, & Melnick A (2008). BCL6 represses CHEK1 and
suppresses DNA damage pathways in normal and malignant B-cells. Blood
Cells Mol Dis 41: 95-99.
Song W, Wang Z, Kan P, Ma Z, Wang Y, Wu Q, et al. (2018).
Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity
of Glioblastoma Cells to TMZ through AKT Pathway. Biomed Res Int
2018: 6953506.
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, & Flowers CR
(2016). 2016 US lymphoid malignancy statistics by World Health
Organization subtypes. CA Cancer J Clin 66: 443-459.
Tomasic T, & Peterlin Masic L (2012). Rhodanine as a scaffold in drug
discovery: a critical review of its biological activities and mechanisms
of target modulation. Expert Opin Drug Discov 7: 549-560.
Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, & Calame
KL (2004). Direct repression of prdm1 by Bcl-6 inhibits plasmacytic
differentiation. J Immunol 173: 1158-1165.
Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, et al.(2017). BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular
Lymphoma Cells. Cancer Discov 7: 506-521.
Wagner SD, Ahearne M, & Ko Ferrigno P (2011). The role of BCL6 in
lymphomas and routes to therapy. Br J Haematol 152: 3-12.
Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, et
al. (2015). The transcriptional modulator BCL6 as a molecular target
for breast cancer therapy. Oncogene 34: 1073-1082.
Wang YQ, Xu MD, Weng WW, Wei P, Yang YS, & Du X (2015). BCL6 is a
negative prognostic factor and exhibits pro-oncogenic activity in
ovarian cancer. Am J Cancer Res 5: 255-266.
Wu HB, Lv WF, Wang YX, Li YY, & Guo W (2018). BCL6 promotes the
methotrexate-resistance by upregulating ZEB1 expression in children with
acute B lymphocytic leukemia. Eur Rev Med Pharmacol Sci 22:5240-5247.
Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE,
et al. (2017). BCL6 promotes glioma and serves as a therapeutic target.
Proc Natl Acad Sci U S A 114: 3981-3986.
Yasui T, Yamamoto T, Sakai N, Asano K, Takai T, Yoshitomi Y, et
al. (2017). Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor
interaction inhibitor by utilizing structure-based drug design. Bioorg
Med Chem 25: 4876-4886.
Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, et
al. (1993). Alterations of a zinc finger-encoding gene, BCL-6, in
diffuse large-cell lymphoma. Science 262: 747-750.